Details of Disease

General Information of Disease (ID: DISBBGVO)

• Disease Name: Gastric ulcer
• Synonyms: chronic gastric ulcer without mention of hemorrhage or perforation, with obstruction; chronic gastric ulcer without mention of haemorrhage or perforation, with obstruction; chronic gastric ulcer without hemorrhage and without perforation but with obstruction; chronic gastric ulcer without hemorrhage and without perforation; chronic gastric ulcer without haemorrhage and without perforation but with obstruction; chronic gastric ulcer without haemorrhage and without perforation; bleeding acute gastric ulcer; acute gastric ulcer without mention of hemorrhage or perforation, without mention of obstruction; acute gastric ulcer without mention of haemorrhage or perforation, without mention of obstruction; acute gastric ulcer without hemorrhage, without perforation and without obstruction; acute gastric ulcer without hemorrhage and without perforation; acute gastric ulcer without haemorrhage and without perforation; acute gastric ulcer with perforation, with obstruction; acute gastric ulcer with perforation and obstruction; acute gastric ulcer with perforation; acute gastric ulcer with hemorrhage, with perforation and with obstruction; acute gastric ulcer with hemorrhage, with obstruction; acute gastric ulcer with hemorrhage and with perforation but without obstruction; acute gastric ulcer with hemorrhage and perforation, without mention of obstruction; acute gastric ulcer with hemorrhage and perforation, with obstruction; acute gastric ulcer with hemorrhage and perforation; acute gastric ulcer with hemorrhage and obstruction; acute gastric ulcer with haemorrhage and with perforation but without obstruction; acute gastric ulcer with haemorrhage and perforation, without mention of obstruction; acute gastric ulcer with haemorrhage and perforation, with obstruction; acute gastric ulcer with haemorrhage and perforation; acute gastric ulcer with haemorrhage and obstruction; stomach peptic ulcer disease; peptic ulcer disease of stomach; gastric ulcer (disease); gastric ulcer
• Disease Class: DA60: Gastric ulcer
• Definition: An ulcerated lesion in the mucosal surface of the stomach. It may progress to involve the deeper layers of the gastric wall.
• Disease Hierarchy:
  DISL8XZI: Peptic ulcer
  DISJLJZ9: Stomach disease
  DISBBGVO: Gastric ulcer
• ICD Code:
  ICD-11: ICD-11: DA60
  ICD-9: ICD-9: 531
  Expand ICD-11: 'DA60
  Expand ICD-10: 'K25; 'K25.0; 'K25.1; 'K25.2; 'K25.3; 'K25.4; 'K25.5; 'K25.6; 'K25.7; 'K25.9
  Expand ICD-9: 531
• Disease Identifiers:
  MONDO ID: MONDO_0001126
  MESH ID: D013276
  UMLS CUI: C0038358
  MedGen ID: 21330
  HPO ID: HP:0002592
  SNOMED CT ID: 397825006

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 9 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Anisotropine Methylbromide	DMIJRF0	Approved	Small molecular drug	[1]
Cimetidine	DMH61ZB	Approved	Small molecular drug	[2]
Famotidine	DMRL3AB	Approved	Small molecular drug	[3]
Lansoprazole	DMXYLQ3	Approved	NA	[4]
Mepenzolate	DM8YU2F	Approved	Small molecular drug	[5]
Methantheline	DM8X4A1	Approved	Small molecular drug	[6]
Nizatidine	DMGFV3Z	Approved	Small molecular drug	[7]
Omeprazole	DM471KJ	Approved	Small molecular drug	[8]
Ranitidine	DM0GUSX	Approved	Small molecular drug	[9]

This Disease is Treated as An Indication in 2 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID26936077-Compound-13	DMXK6LV	Patented	Small molecular drug	[10]
PMID26936077-Compound-34	DMIZL8D	Patented	Small molecular drug	[10]

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CP-66948	DMTM0UI	Discontinued in Phase 1	Small molecular drug	[11]
TRM-115	DMSFV9T	Discontinued in Phase 1	Small molecular drug	[12]
Z-300	DMA412G	Discontinued in Phase 1	Small molecular drug	[13]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 38 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
PTGER1	TTG1QMU	Limited	Therapeutic	[14]
ANGPT2	TTKLQTJ	moderate	Biomarker	[15]
BCL2L1	TTRE6AX	moderate	Therapeutic	[16]
CASP3	TTPF2QI	moderate	Therapeutic	[17]
CFTR	TTRLZHP	moderate	Therapeutic	[18]
COL18A1	TT63DI9	moderate	Biomarker	[19]
F13A1	TTXI2RA	moderate	Biomarker	[20]
FAS	TT7LTUJ	moderate	Therapeutic	[17]
FASLG	TTO7014	moderate	Therapeutic	[17]
HRH3	TT9JNIC	moderate	Biomarker	[21]
IDUA	TT0IUKX	moderate	Biomarker	[22]
MAPK1	TT4TQBX	moderate	Biomarker	[23]
MAPK3	TT1MG9E	moderate	Biomarker	[23]
MMP13	TTHY57M	moderate	Biomarker	[24]
MMP3	TTUZ2L5	moderate	Biomarker	[24]
OXTR	TTSCIUP	moderate	Biomarker	[25]
S100A8	TT4AF6N	moderate	Biomarker	[26]
ADM	TTV14YH	Strong	Therapeutic	[27]
AGT	TT5C0UB	Strong	Therapeutic	[28]
ANGPT1	TTWNQ1T	Strong	Altered Expression	[29]
BDKRB1	TTG5QIA	Strong	Altered Expression	[30]
CAT	TTPS279	Strong	Biomarker	[31]
CCK	TT90CMU	Strong	Biomarker	[32]
EGF	TTED8JB	Strong	Therapeutic	[33]
EPO	TTQG4NR	Strong	Therapeutic	[34]
GHRL	TT1OCL0	Strong	Therapeutic	[35]
IAPP	TTHN8EM	Strong	Therapeutic	[36]
LEP	TTBJEZ5	Strong	Therapeutic	[37]
MMP9	TT6X50U	Strong	Biomarker	[38]
MUC5AC	TTEL90S	Strong	Biomarker	[39]
NOS3	TTCM4B3	Strong	Therapeutic	[40]
NRG1	TTEH395	Strong	Biomarker	[41]
PGC	TT7K6AD	Strong	Genetic Variation	[42]
PTGS1	TT8NGED	Strong	Biomarker	[43]
SST	TTWF7UG	Strong	Biomarker	[44]
TEK	TT9VGXW	Strong	Altered Expression	[45]
TFF1	TTNOJIZ	Strong	Altered Expression	[46]
NOS2	TTF10I9	Definitive	Biomarker	[47]

This Disease Is Related to 11 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
TFF2	OTRXB19X	Disputed	Altered Expression	[46]
BAD	OT63ERYM	moderate	Therapeutic	[16]
FOXO4	OT90X9LN	moderate	Biomarker	[48]
HLA-DPA1	OT7OG7Y2	moderate	Biomarker	[49]
OXT	OT48M72Z	moderate	Biomarker	[25]
TIMP1	OTOXC51H	moderate	Biomarker	[24]
DMC1	OT1FHMW4	Strong	Biomarker	[50]
EFNA5	OTOH4DRR	Strong	Biomarker	[51]
HID1	OTVJIFSU	Strong	Biomarker	[50]
MLN	OTBZ5SE5	Strong	Biomarker	[44]
MUC6	OTPVL723	Strong	Biomarker	[52]

References

• [1] Anisotropine Methylbromide FDA Label
• [2] Cimetidine FDA Label
• [3] Famotidine FDA Label
• [4] Lansoprazole FDA Label
• [5] Mepenzolate FDA Label
• [6] Methantheline FDA Label
• [7] Nizatidine FDA Label
• [8] Omeprazole FDA Label
• [9] Ranitidine FDA Label
• [10] Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001137)
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002138)
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001448)
• [14] The roles of prostaglandin E receptor subtypes in the cytoprotective action of prostaglandin E2 in rat stomach. Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:116-24.
• [15] Expression of Tie-2 and angiopoietin-1 and -2 in early phase of ulcer healing.J Gastroenterol. 2003;38(5):431-5. doi: 10.1007/s00535-002-1078-3.
• [16] Cytoprotective effect of American ginseng in a rat ethanol gastric ulcer model.Molecules. 2013 Dec 27;19(1):316-26. doi: 10.3390/molecules19010316.
• [17] Prophylactic efficacy of patchoulene epoxide against ethanol-induced gastric ulcer in rats: Influence on oxidative stress, inflammation and apoptosis.Chem Biol Interact. 2018 Mar 1;283:30-37. doi: 10.1016/j.cbi.2018.01.014. Epub 2018 Jan 12.
• [18] [Effects of weile powder on bicarbonate transporters CFTR SLC26A3 and SLC26A6 in gastric ulcers of rats].Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 Jan;33(1):81-4.
• [19] Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release.Proc Natl Acad Sci U S A. 2001 May 22;98(11):6470-5. doi: 10.1073/pnas.111150798. Epub 2001 May 15.
• [20] Factor XIII improves gastric stress lesions in rats.Digestion. 2001;63(4):220-8. doi: 10.1159/000051893.
• [21] Role of capsaicin-sensitive nerves and histamine H1, H2, and H3 receptors in the gastroprotective effect of histamine against stress ulcers in rats.Eur J Pharmacol. 2005 Jan 31;508(1-3):211-21. doi: 10.1016/j.ejphar.2004.11.059. Epub 2004 Dec 30.
• [22] [Changes in the activities of lysosomal enzyme (glycosidase) in experimental acute gastric mucosal lesion].Nihon Geka Gakkai Zasshi. 1986 Apr;87(4):395-402.
• [23] [Effect of moxibustion intervention on expression of gastric epidermal growth factor receptor and extracellular signal regulated kinase 1/2 expression in rats with gastric ulcer].Zhen Ci Yan Jiu. 2014 Oct;39(5):351-7.
• [24] Spatial and temporal pattern of expression of interstitial collagenase, stromelysin/transin, gelatinase A, and TIMP-1 during experimental gastric ulcer healing.Digestion. 2004;70(2):127-38. doi: 10.1159/000080931. Epub 2004 Sep 16.
• [25] Gastric antisecretory and antiulcer activity of oxytocin in rats and guinea pigs.Life Sci. 2001 Nov 21;70(1):17-24. doi: 10.1016/s0024-3205(01)01376-5.
• [26] Prevalence, diversity and disease association of Helicobacter pylori in dyspeptic patients from Pakistan.J Infect Dev Ctries. 2013 Mar 14;7(3):220-8. doi: 10.3855/jidc.2942.
• [27] Effects of centrally of peripherally injected adrenomedullin on reserpine-induced gastric lesions.Eur J Pharmacol. 1998 Oct 30;360(1):51-4. doi: 10.1016/s0014-2999(98)00688-8.
• [28] Angiotensin (1-7) protects against stress-induced gastric lesions in rats.Biochem Pharmacol. 2014 Feb 1;87(3):467-76. doi: 10.1016/j.bcp.2013.10.026. Epub 2013 Nov 11.
• [29] Gene therapy for ulcerations of the gastrointestinal tract.Drugs Today (Barc). 2006 Mar;42(3):193-203. doi: 10.1358/dot.2006.42.3.893620.
• [30] Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms.Int Immunopharmacol. 2001 Nov;1(12):2063-80. doi: 10.1016/s1567-5769(01)00118-7.
• [31] Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats.J Pharmacol Sci. 2007 Sep;105(1):94-102. doi: 10.1254/jphs.fp0070122.
• [32] Involvement of capsaicin-sensitive afferent nerves and cholecystokinin 2/gastrin receptors in gastroprotection and adaptation of gastric mucosa to Helicobacter pylori-lipopolysaccharide.J Pharmacol Exp Ther. 2004 Jul;310(1):116-25. doi: 10.1124/jpet.104.065128. Epub 2004 Mar 15.
• [33] Importance of nitric oxide and capsaicin-sensitive afferent nerves in healing of stress lesions induced by epidermal growth factor.J Clin Gastroenterol. 1997;25 Suppl 1:S28-38. doi: 10.1097/00004836-199700001-00007.
• [34] The role of erythropoietin in the protection of gastric mucosa from indometacin-induced gastric injury and its relationship with oxidant and antioxidant parameters in rats.J Pharm Pharmacol. 2010 Jan;62(1):85-90. doi: 10.1211/jpp.62.01.0009.
• [35] Role of central and peripheral ghrelin in the mechanism of gastric mucosal defence.Inflammopharmacology. 2005;13(1-3):45-62. doi: 10.1163/156856005774423971.
• [36] Effect of amylin in various experimental models of gastric ulcer.Eur J Pharmacol. 1997 Aug 6;332(2):209-13. doi: 10.1016/s0014-2999(97)01081-9.
• [37] Gastroprotective effect of leptin in indomethacin-induced gastric injury.J Biomed Sci. 2008 May;15(3):405-12. doi: 10.1007/s11373-007-9227-6. Epub 2008 Jan 8.
• [38] Novel role of famotidine in downregulation of matrix metalloproteinase-9 during protection of ethanol-induced acute gastric ulcer.Free Radic Biol Med. 2007 Jul 15;43(2):289-99. doi: 10.1016/j.freeradbiomed.2007.04.027. Epub 2007 Apr 29.
• [39] Synthesis and in vivo anti-ulcer evaluation of some novel piperidine linked dihydropyrimidinone derivatives.J Enzyme Inhib Med Chem. 2018 Dec;33(1):978-988. doi: 10.1080/14756366.2018.1474212.
• [40] Exendin-4, a glucagon-like peptide-1 analogue accelerates healing of chronic gastric ulcer in diabetic rats.PLoS One. 2017 Nov 2;12(11):e0187434. doi: 10.1371/journal.pone.0187434. eCollection 2017.
• [41] Heregulin-alpha and heregulin-beta expression is linked to a COX-2-PGE2 pathway in human gastric fibroblasts. Am J Physiol Gastrointest Liver Physiol. 2006 Jun;290(6):G1243-51. doi: 10.1152/ajpgi.00253.2005. Epub 2005 Dec 15.
• [42] Impact of pepsinogen C polymorphism on individual susceptibility to gastric cancer and its precancerous conditions in a Northeast Chinese population.J Cancer Res Clin Oncol. 2009 Aug;135(8):1033-9. doi: 10.1007/s00432-008-0539-3. Epub 2009 Jan 9.
• [43] Design, synthesis and analgesic/anti-inflammatory evaluation of novel diarylthiazole and diarylimidazole derivatives towards selective COX-1 inhibitors with better gastric profile. Bioorg Med Chem. 2017 Jan 15;25(2):665-676.
• [44] 1-Deoxynojirimycin (DNJ) Ameliorates Indomethacin-Induced Gastric Ulcer in Mice by Affecting NF-kappaB Signaling Pathway.Front Pharmacol. 2018 Apr 19;9:372. doi: 10.3389/fphar.2018.00372. eCollection 2018.
• [45] IL-11 up-regulates Tie-2 expression during the healing of gastric ulcers in rats.World J Gastroenterol. 2003 Apr;9(4):788-90. doi: 10.3748/wjg.v9.i4.788.
• [46] Expression of trefoil factors 1 and 2 in precancerous condition and gastric cancer.World J Gastroenterol. 2006 May 21;12(19):3119-22. doi: 10.3748/wjg.v12.i19.3119.
• [47] Improved antiulcer and anticancer properties of a trans-resveratrol analog in mice.J Pharmacol Exp Ther. 2009 Mar;328(3):829-38. doi: 10.1124/jpet.108.145334. Epub 2008 Dec 9.
• [48] Effect of the IGF-1/PTEN/Akt/FoxO signaling pathway on the development and healing of water immersion and restraint stress-induced gastric ulcers in rats.Int J Mol Med. 2012 Sep;30(3):650-8. doi: 10.3892/ijmm.2012.1041. Epub 2012 Jun 20.
• [49] Contribution of major histocompatibility complex genes to susceptibility and resistance in Helicobacter pylori related diseases.Eur J Gastroenterol Hepatol. 1999 Aug;11(8):875-80. doi: 10.1097/00042737-199908000-00011.
• [50] Gastroprotective potential of methanolic extract and dimethyl cardamonin from Campomanesia reitziana fruits in mice.Naunyn Schmiedebergs Arch Pharmacol. 2017 Jun;390(6):661-666. doi: 10.1007/s00210-017-1369-0. Epub 2017 Apr 1.
• [51] Transgenic domestic animals provide an animal model for rheumatoid arthritis.Med Hypotheses. 1992 Jul;38(3):240-3. doi: 10.1016/0306-9877(92)90102-i.
• [52] Quantitative MUC5AC and MUC6 mucin estimations in gastric mucus by a least-squares minimization method.Anal Biochem. 2013 Aug 15;439(2):204-11. doi: 10.1016/j.ab.2013.04.013. Epub 2013 Apr 30.